The purpose of the study was to evaluate the relationship between the 1-yr (n ϭ 193) and 2-yr (n ϭ 128) growth response and the individual serum concentrations of insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) before and during GH treatment. Our study group of prepubertal short children had from very low to high GH secretory capacity, estimated during an arginineinsulin tolerance test, and the ages ranged from 3-15 yr at the start of treatment. Their serum levels of IGF-I and IGFBP-3 were low before treatment compared to those in an age-related reference group of prepubertal children and increased significantly from the start to 1 month of GH treatment. The mean increase in height SD score was 0.80 SD score after 1 yr of GH treatment and 1.26 SD score after 2 yr, with a wide range. In univariate analyses the highest correlation coefficients to the 2-yr growth response were found to be vs. the following variables from the start of treatment: IGF-I SD score (r ϭ Ϫ0.49), log maximum GH concentration (log GH max ) during the arginine-insulin tolerance test (r ϭ Ϫ0.47), difference between the height SD score of the individual child and the midparental height SD score (diffSD score; r ϭ Ϫ0.45), IGFBP-3 SD score (r ϭ Ϫ0.39), age (r ϭ Ϫ0.30), short term change in IGFBP-3 SD score (r ϭ 0.37), and IGF-I SD score (r ϭ 0.34). In multivariate stepwise regression analysis, 41% of the variation in the 2-yr growth response could be explained by IGF-I SD score or log GH max together with age at the start of treatment, weight SD score at 1 yr of age, and diffSD score. When both IGF-I SD score and GH max were included and when the short term changes in IGF-I SD score were added, 46% and 58% of the variation, respectively, could be explained. The regression algorithms using different combinations of variables and their corresponding prediction intervals are also presented.
Ϫ0.49), log maximum GH concentration (log GH max ) during the arginine-insulin tolerance test (r ϭ Ϫ0.47), difference between the height SD score of the individual child and the midparental height SD score (diffSD score; r ϭ Ϫ0.45), IGFBP-3 SD score (r ϭ Ϫ0.39), age (r ϭ Ϫ0.30), short term change in IGFBP-3 SD score (r ϭ 0.37), and IGF-I SD score (r ϭ 0.34). In multivariate stepwise regression analysis, 41% of the variation in the 2-yr growth response could be explained by IGF-I SD score or log GH max together with age at the start of treatment, weight SD score at 1 yr of age, and diffSD score. When both IGF-I SD score and GH max were included and when the short term changes in IGF-I SD score were added, 46% and 58% of the variation, respectively, could be explained. The regression algorithms using different combinations of variables and their corresponding prediction intervals are also presented. (J Clin Endocrinol Metab 82: 2889 -2898, 1997) S ELECTING children who will benefit from GH treatment is still a challenge despite nearly 40 yr of experience. Earlier studies of the growth response to GH treatment often used groups of short children defined either as GH-deficient/insufficient, i.e. with a maximum GH level (GH max ) during a pharmacological stimulation test below a certain arbitrary level, or defined as having normal GH secretion, i.e. GH max during a stimulation test above the cut-off level. Several studies have shown that serum GH concentrations during GH provocation tests and 24-h GH profiles as well as serum concentrations of insulin-like growth factor I (IGF-I) in groups of children defined as GH deficient overlap with the serum concentrations of GH and IGF-I in groups of non-GH-deficient children of short and/or normal stature (1, 2) . Moreover, most short children increase their growth rate during GH therapy regardless of the diagnosis of GH deficiency (GHD) or idiopathic short stature (3) (4) (5) (6) (7) (8) . In fact, only children with GH insensitivity syndrome will not respond to GH treatment (9) .
With the diagnostic criteria used worldwide today, children with very low pituitary GH secretory capacity can be identified. Various GH provocation tests have been used in an attempt to identify predictors of the growth response to GH treatment (10 -12) or in diagnosing GHD, sometimes together with biochemical parameters, such as basal levels of IGF-I and IGF-binding protein-3 (IGFBP-3) (1, 13) or their short term changes during GH treatment (14) .
The aim of this study was to evaluate an alternative diagnostic approach to possible GH treatment of a short child without using a cut-off serum level of GH during the stimulation test as the crucial value. The relationship between the 1-and 2-yr growth responses to GH treatment and the basal levels of both IGF-I and IGFBP-3 and their short term changes was evaluated in a group of prepubertal short children with different GH secretory capacities, estimated by a stimulation test, together with auxology variables.
Subjects and Methods

Study group
A group of 193 short healthy prepubertal Swedish children (30 girls and 163 boys) with a broad range of GH max in response to an arginineinsulin tolerance test (AITT; 0 -104 mU/L) were treated daily with GH (0.1 IU/kg) and followed during treatment for 1 yr (n ϭ 193) or 2 yr (n ϭ 128). The patients were either children with isolated idiopathic GHD, defined as having GH max below 32 mU/L using the WHO International Reference Preparation (IRP) 80/505 (or Ͻ20 mU/L using the WHO IRP 66/217), reported to the Swedish National Registry for GH treatment (n ϭ 117) or short children without GHD, defined as having a GH max above 32 mU/L, included in national clinical trials with GH treatment (n ϭ 76).
All children were well nourished and had normal thyroid, liver, and kidney functions. Children with coeliac disease were excluded, and the children were free from chronic disease and dysmorphic syndromes. All children had a gestational age (GA) at birth of more than 30 weeks, and their birth weights and birth lengths were Ϫ2.5 sd score or more for gestational age (15) . The characteristics of the patients are given in Table 1 .
Study protocol
Pretreatment investigations. The endocrine investigation was performed during the pretreatment year. The children underwent an AITT according to the protocol described previously, and the GH max was used for the analysis (12) .
Treatment follow-up. All children underwent the same regimen of daily GH treatment (0.1 IU/kg). Blood samples were taken at the start of treatment and after 10 and/or 30 days, 3 months, 1 yr, and 2 yr of treatment for analysis of serum concentrations of IGF-I and IGFBP-3. The samples were mostly taken between 1400 -1800 h, i.e. nearly 24 h after the latest GH injection. Measurements of IGF-I and IGFBP-3 were used only when the child was healthy; any known ongoing infection meant that the blood samples were excluded from the analysis for the prediction models. Serum samples were kept frozen until measurement of GH, IGF-I, and IGFBP-3.
The studies were approved by the ethical committees of the Medical Faculties of the Universities of Goteborg, Lund, Uppsala, Linkoping, and Umea and the Karolinska Institute in Stockholm. Informed consent was obtained from the parents of each child and from the child, if old enough.
Auxology
Information on GA, birth weight, and birth length was collected from the obstetric report on the mothers kept at the Medical Birth Registry. The growth of the children was recorded at health care units from birth to inclusion in the study, i.e. 1 yr before the start of GH treatment. Thereafter, height was measured using a Harpenden stadiometer at the pediatric units. Height parameters were transformed into sd score, corrected for sex and age using the childhood component of the infancychildhood-puberty (ICP) growth model of Karlberg (16) , weight parameters according to Karlberg et al. (17) , and weight for height sd score (WH sd score sd score), i.e. weight sd score-␤ ϫ height sd score, according to the method of Karlberg and Albertsson-Wikland (18, 19) . Midparental height was expressed as the sd score compared with Swedish reference values (17) . The difference between the height sd score of each child at the start of treatment and the midparental height expressed as the sd score (diffsd score) was calculated.
Hormone analysis
GH. Measurements of GH during the AITT were performed in different laboratories (n ϭ 86) using a polyclonal antibody-based immunoradiometric assay (Pharmacia & Upjohn, Uppsala, Sweden) with WHO IRP 80/505 as the standard. During 1991 and 1992, the laboratories in Sweden switched from WHO IRP 66/217 to WHO IRP 80/505, which meant that a conversion factor of 1.55 had to be used to compare the results of GH levels (n ϭ 107) (19, 20) .
IGF-I.
Concentrations of IGF-I were measured by an IGFBP-blocked RIA without extraction and in the presence of an approximately 250-fold excess of IGF-II (Mediagnost, Tubingen, Germany) (21) . The intraassay coefficients of variation were 8.1%, 4.4%, and 4.5% at concentrations of 55, 219, and 479 g/L, respectively, and the interassay coefficients of variation were 10.4%, 7.7%, and 5.3% at concentrations of 55, 219, and 479 g/L, respectively.
IGFBP-3.
Concentrations of IGFBP-3 were determined using a previously reported RIA method (21) . The intraassay coefficients of variation were 6.2%, 5.6%, and 4.6% at concentrations of 1964, 2927, and 4799 g/L, respectively, and the interassay coefficients of variation were 6.8%, 9.2%, and 6.9% at concentrations of 1964, 2927, and 4799 g/L, respectively. As serum concentrations of IGF-I and IGFBP-3 are age dependent (22) , the values were converted into sd score using a prepubertal reference, obtained in our laboratory from healthy children of normal (Ϯ2 sd) stature (23) .
The following variables were included in the correlation analysis to the growth response: sex; GA; age at onset of the childhood component in the ICP model; weight, length, WH sd score sd score at birth and at 1 and 2 yr of age, and 1 yr before and at the start of GH treatment; together with the change in height, weight, and WH sd score sd score between birth and 1 yr and between birth and 2 yr of age. Also included were the yearly change in height, weight, and WH sd score sd score from 1 yr of age to the start of treatment and from 2 yr of age to the start of treatment together with the same auxological changes during the pretreatment year. The auxological information from birth to 2 yr of age was referred to as early growth. Maternal and paternal height sd scores as well as midparental height sd score were included in the analysis together with the diffsd score and the difference in height sd score between the child at the start of treatment and maternal and paternal height sd scores separately.
Included in the statistical analyses were the individual basal levels of IGF-I and IGFBP-3, expressed as the sd score, and levels at 10 and/or 30 days (at either time or the mean) and 3 months together with the individual differences between the level at 10 and/or 30 days or 3 months and the level at the start of treatment. Also included was the ratio of IGF-I sd score/IGFBP-3 sd score for each child and the change from the start of treatment to 10 and/or 30 days and to 3 months. The GH values were log transformed before statistical analysis.
Bone age estimations are not included in the analysis due to missing information from a number of patients.
Statistical analyses
For testing changes over time, Fisher's nonparametric permutation test for paired observations was used; for comparison between groups, Fisher's nonparametric permutation test was used. Correlations were tested using Pitman's nonparametric permutation test (24) . Pearson's correlation coefficients were used only for descriptive purposes. Exclusively variables correlated (P Ͻ 0.10) with the growth response were entered into a multiple stepwise forward linear regression analysis.
Results
Changes in IGF-I levels
The serum concentrations of IGF-I in individual children at the start of GH treatment and after 1 and 2 yr of treatment compared with the age-related prepubertal reference values are shown in Fig. 1 (top panel) . After 1 and 3 months of treatment, the mean IGF-I sd score for the group did not differ from the reference group and did not change significantly during the following 2 yr (Table 1) .
Compared with the level at the start of treatment, there was a highly significant change in individual serum IGF-I levels. Expressed as the sd score (sd, range) and shown in Fig.  2 , the change from the start to 10 and/or 30 days of GH treatment was 1.26 (0.90, Ϫ0.82 to 4.69; n ϭ 152; P Ͻ 0.0001), that from the start to 3 months of treatment was 1.47 (0.89, Ϫ0.90 to 5.16; n ϭ 142; P Ͻ 0.0001), that from the start to 1 yr was 1.71 (1.13, Ϫ0.98 to 6.01; n ϭ 161; P Ͻ 0.0001), and that from the start to 2 yr was 1.66 (1.19, Ϫ1.32 to 5.03; n ϭ 95; P Ͻ 0.0001). For those 83 children measured at both 1 and 2 yr of treatment, there was no significant difference in the individual IGF-I sd score between these two points [0.07 (0.92, Ϫ3.26 to 2.13; n ϭ 83; P ϭ NS].
Changes in IGFBP-3 levels
The serum concentrations of IGFBP-3 in individual children at the start of GH treatment and after 1 and 2 yr of treatment compared with reference values are shown in Fig.  1 (bottom panel) . For IGF-I, the mean IGFBP-3 sd score of the group was in the normal range after 1 month of treatment and did not change significantly during the following 2 yr ( Table 1) .
The mean increase in individual serum concentrations of IGFBP-3, expressed as the sd score (sd, range), from the start to 10 and/or 30 days of GH treatment was 1.10 (0.83, Ϫ0.95 to 4.17; n ϭ 151; P Ͻ 0.0001), that from the start to 3 months 
Growth response
The mean increase in height sd score (sd, range) during the first year of GH treatment was 0.80 (0.34, 0.08 to 2.27; P Ͻ 0.0001 compared with the pretreatment year change in height sd score) and during the second year was 0.46 (0.25, Ϫ0.11 to 1.51; P Ͻ 0.0001 compared with the pretreatment year change in height sd score). After 2 yrs of treatment, the mean total height gain was 1.26 sd score (0.53, 0.42 to 3.14; P Ͻ 0.0001 compared with the pretreatment year). There was considerable interindividual variation in the response, even though none of the children was known to be noncompliant (Fig. 3, top panel) .
The mean attained height at the start of treatment (sd, range) was Ϫ2.74 (0.69, Ϫ6.00 to Ϫ1.12), Ϫ1.94 (0.72, Ϫ4.49 to 0.26) after 1 yr, and Ϫ1.57 (0.84, Ϫ3.58 to 1.25) after 2 yr (Fig. 3, middle panel) .
The growth response can also be expressed as the diminishing distance to the individual midparental height, expressed as the sd score. This mean difference (sd, range), was Ϫ1.95 (1.07, Ϫ6.16 to 0.46) at the start of treatment, Ϫ1.08 (0.90, Ϫ4.65 to 1.21) after 1 yr of treatment, and Ϫ0.70 (0.90, Ϫ4.22 to 1.05) after 2 yr of treatment. During these 2 yr of treatment, the children were showing catch-up growth and were approaching their appropriate target height (Fig. 3,  bottom panel) .
Correlation of the growth response to GH treatment
Univariate analysis. The variables that correlated (P Ͻ 0.10, by Pitman's permutation test) to the growth response after 1 or 2 yr of GH treatment are presented together with the correlation coefficients in Table 2 . The correlation to IGF-I and IGFBP-3 variables are shown in Fig. 4 and to other variables selected in the multivariate analysis in Fig. 5 . Note the broad range in GH max during the AITT as well as the continuum in the growth response.
The correlation coefficient between the IGF-I sd score at the start of treatment and the IGFBP-3 sd score was 0.76 (P Ͻ 0.0001) and that between IGF-I sd score at the start of treatment and log GH max at AITT was 0.34 (P Ͻ 0.0001). When the IGFBP-3 sd score was compared with log GH max at AITT, the correlation coefficient was 0.43 (P Ͻ 0.0001). There was a week correlation between the GH max at AITT and the short term (10 and/or 30 days) change in IGF-I sd score or IGFBP-3 sd score (r ϭ Ϫ0.20; P Ͻ 0.05 for both).
Multivariate analysis. In the initial linear regression analysis, the commonly used variables when diagnosing GHD were included: parental heights, pretreatment growth pattern, age, and GH max at AITT. The GH max at AITT was the first selected variable, followed, in order of selection, by diffsd score, attained weight sd score at 1 yr of age, and age at the start of treatment (analysis 1, Table 3 ); these variables accounted for 41% of the variance in the growth response.
In the next analysis, the IGF-I sd score and IGFBP-3 sd score were included, whereas GH values were excluded (analysis 2a). The same level of variance (41%) in the growth response was explained, with the IGF-I sd score being the most informative variable. Thus, the IGF-I sd score was as informative as the GH max at AITT at the start of treatment.
In the third analysis, both the GH max from the AITT together with the IGF-I sd score and the IGFBP-3 sd score were included (analysis 3a). This resulted in a small increase in the level of variance that could be explained (46%). The highest level of explanation of the variance (58%) was obtained when the GH max from the AITT and the IGF-I sd score at the start of treatment together with short term changes in the IGF-I sd score after the start of GH treatment were combined (analysis 3b). When only the variables most often available in a clinical setting at the start of treatment were included, i.e. auxology during the pretreatment year, parental heights, IGF-I sd score, and IGFBP-3 sd score, but not GH values or the auxological information from before 3 yr of age (here described as early growth), the following order of selection was obtained, predicting the 2 yr growth response: IGF-I sd score at the start, age at the start, midparental height sd score, and change in WH sd score sd score during the pretreatment year; these variables explained 39% of the variance (analysis 4a). Adding the short term changes (both 10 and/or 30 days and 0 -3 months) in the IGF-I sd score and the IGFBP-3 sd score, the 0 -3 months change in IGF-I sd score was selected, and the variance that now could be explained was 43% (analysis 4b). The estimated regression algorithms for the yearly 2-yr growth response, based on the different variables used in each model, are shown in Table 3 .
The regression algorithms for the 1-yr growth response were also calculated. Using almost the same variables, 0% (analysis 4a) to 12% (analysis 3b) less of the variance could be explained.
Using the different regression algorithms presented in Table 3, a 95% prediction interval was calculated, using the mean values, Ϯ1sd, and Ϯ2sd for the included variables (reminding the reader that the amplitude of the prediction interval is wider than the amplitude of the 95% confidence interval of the algorithm). The values obtained are presented in Table 3 , right column. An illustration of the pretreatment growth and the prediction interval of the 2-yr growth response for one boy, with growth response about the mean of the group, is shown in Fig. 6 .
Discussion
Our study can be seen as an attempt to mathematically/ statistically evaluate the clinical information we already are using. When using the classic diagnostic criteria for GH deficiency, we have previously shown that it is possible to explain only 33% of the variation in the growth response (12) . In the present study it was possible to explain 41% of the variance in the 2-yr growth response when the infancy growth data from the child were included together with the growth during the pretreatment year, parental heights, and GH max at AITT. Replacing the GH max at AITT by the IGF-I sd score and the IGFBP-3 sd score at the start of treatment, the IGF-I sd score was selected, and the level of explanation could be maintained. As much as 58% of the variance in the 2-yr growth response could be explained using the variables age at the start of treatment, GH max at AITT, IGF-I sd score at the start of treatment, and change in the IGF-I sd score during the first 3 months of treatment. Thus, by increasing the included information about the child, the explained variation in growth response increased from 33% to 58%.
According to these results, there is the possibility of using distance after 1 and 2 yr of treatment. Box and whisker plots indicate the median, lower, and upper quartiles, and the whiskers show the 1st and 99th percentiles. The mean values are depicted as solid circles in each plot.
FIG. 3.
Top, Growth response, expressed as change in the height SD score, of the study group of short children with different GH status during the pretreatment year and during the first, second, and 2-yr periods of GH treatment (0.1 IU/kg⅐day). Middle, Attained height SD score of the group at 1 yr before, at the start, and after 1 and 2 yr of GH treatment. The group mean midparental height is indicated (dashed line) Ϯ 1 SD (dotted lines). Bottom, Growth response to GH treatment, expressed as the distance to the individual midparental height SD score at the start of treatment and as the diminishing either the GH max at AITT or the IGF-I sd score at the start of treatment to predict the growth response, but the explanation level is still limited. Both means of investigation have their disadvantages; GH max at AITT may be falsely low because of refractoriness of the somatotrophs at the time of provocation (25, 26) , beside its clinical disadvantage, and IGF-I is markedly dependent not only on GH but also on nutritional factors. We found that the transformation of IGF-I and IGFBP-3 into the sd score, relevant for age and pubertal stage, was very important, as the level of explanation was much lower when absolute values were used (data not shown).
In our patient group, both IGF-I-and IGFBP-3-values were available at each occasion that blood was sampled. The values were strongly correlated with each other, and like results in earlier studies, where IGFBP-3 has been shown to be a reliable reflector of the GH secretion (13, 27) , this was also found in this study group, with the IGFBP-3 sd score having a higher correlation coefficient to GH max at AITT than the IGF-I sd score. However, regarding the growth response to GH treatment, although IGF-I and IGFBP-3 levels at the start of treatment were each negatively correlated with the 1-and 2-yr growth responses, in this study the IGF-I value was selected as the most informative variable of the two. In a more heterogeneous group of children or in a clinical setting, it can be wise to measure both the IGF-I sd score and the IGFBP-3 sd score, because of the stability over time of the latter. If the levels are discordant, additional evaluation may be indicated. The serum IGF-I concentrations for the whole group were low at the start of GH treatment, but were within the reference range after 1 and 2 yr of treatment in most children. This indicates that the dose of GH given was not too high for most of the children, as we did not find high IGF-I concentrations during treatment. However, the reference ranges of IGF-I and IGFBP-3 are wide, and some children in our study attained high values during treatment, whereas others still had low values. This variability illustrates the need for using individual GH treatment regimens that take account of the variability in individual sensitivity of the GH/IGF-I axis, as reflected by individual IGF-I levels. The variability in the growth response in the present heterogeneous group of short children was expected and reflects the individual differences in tissue responsiveness to GH. Because all children were treated with the same GH regimen, we did not have to consider the effects of different GH doses and injection frequencies, which have been shown to be important contributory factors to the growth response to GH treatment (28, 29) . Ranke and Guilbaud (30) and Blethen et al. (10) have shown that the dose and frequency of injections are important predictors of growth in children with GHD and certainly in children with idiopathic short stature (31) . Some of the short children in our study group were probably partially GH resistant (32, 33) , although we were unable to assess GH-binding protein levels in a sufficient number of children to include this variable in the analysis. However, Attie et al. (34) showed that in prepubertal children, the growth response to GH treatment did not differ between groups with low or normal GH-binding protein levels.
We conclude that this group of short prepubertal children with a wide range of GH status has reduced serum concentrations of IGF-I and IGFBP-3 compared with those in healthy children of normal height. Treatment with GH (0.1 IU/kg⅐day) normalized the levels of IGF-I and IG-FBP-3 for most, but not all, children. There was a broad range in the growth response to GH treatment, which could be best explained by chronological age (the younger the better) and diffsd score (the higher the better). These variables together with the IGF-I sd score at the start of treatment and the GH max at AITT (the lower the better for both) accounted for about 41-46% of the variability in the 2-yr growth response. The IGF-I sd score and AITT GH max were interchangeable in the prediction model, as were GH max at AITT and short term changes in IGF-I sd score during treatment. Although both IGF-I and IGFBP-3 were highly correlated, and both correlated with the growth response, IGF-I was the more informative in explaining the variation in growth response.
Thus, there are two alternatives, to use either the GH max at AITT or the IGF-I sd score, when predicting the 2-yr growth response before possible GH treatment of a short child. With all of the variables used now, as much as 58% of the variance in the growth response could be explained. This is, to our knowledge, the highest level of explanation presented to date for a study group such as this. However, when using our estimated regression algorithms to construct the prediction intervals, the range in yearly growth response is still wide (about Ϯ0.4 sd) even given the now available combinations of tests and baseline variables. In clinical work, when selecting children for GH treatment, it is valuable to know the calculated estimate of the predictive value of different combinations of variables, although it is low. Thus, the search for better indicators of the individual growth responsiveness to GH treatment should continue. 6 . The growth chart from one of the boys before and after the start of GH treatment (arrow at 7.1 yr) with the prediction interval after 2 yr of treatment (mean Ϯ 1 and 2SD), according to analysis 3a, with his individual pretreatment values included into the algorithm.
